Cargando…

Suicide in European Hodgkin Lymphoma Patients

The purpose of this study was to determine whether there is an increased risk of suicide in European Hodgkin Lymphoma (HL) patients compared to the general European population. European HL patients enrolled in the German Hodgkin Study Group (GHSG) HD7 through HD15 studies were analyzed and standardi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Austin I., Goergen, Helen, Engert, Andreas, LaCasce, Ann S., Maranda, Louise, Barton, Bruce, Borchmann, Sven
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6746042/ https://www.ncbi.nlm.nih.gov/pubmed/31723822 http://dx.doi.org/10.1097/HS9.0000000000000183

Ejemplares similares

Examining rare side effects in pooled trial data: symptomatic osteonecrosis in Hodgkin lymphoma
por: Borchmann, Sven, et al.
Publicado: (2018)

Hodgkin Lymphoma has a seasonal pattern of incidence and mortality that depends on latitude
por: Borchmann, Sven, et al.
Publicado: (2017)

Epstein Barr Virus Associated B-Cell Lymphomas and Iatrogenic Lymphoproliferative Disorders
por: Crombie, Jennifer L., et al.
Publicado: (2019)

The Phase 3 Study ECHELON-1 Evaluating Brentuximab Vedotin in Patients With Newly Diagnosed Hodgkin Lymphoma Leaves Important Questions Unanswered
por: Borchmann, Peter, et al.
Publicado: (2018)

Nivolumab in Relapsed/Refractory Classical Hodgkin Lymphoma – Extended Follow-up of 30 Patients Treated Within the CheckMate 205 Trial in a Single-Center
por: Momotow, Jesko, et al.
Publicado: (2019)

Hodgkin Lymphoma—Review on Pathogenesis, Diagnosis, Current and Future Treatment Approaches for Adult Patients
por: Momotow, Jesko, et al.
Publicado: (2021)

The International Prognostic Index: still relevant 30 years later
por: LaCasce, Ann S.
Publicado: (2023)

Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group
por: Damaschin, Carla, et al.
Publicado: (2021)

Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma
por: Abramson, Jeremy S., et al.
Publicado: (2022)

P063: Trial in Progress: Individualized Immunotherapy in Early-Stage Unfavorable Hodgkin Lymphoma - The Investigator-Initiated Phase II GHSG INDIE Trial
por: Bröckelmann, Paul J., et al.
Publicado: (2022)

Reduced-Intensity Chemotherapy in Patients With Advanced-Stage Hodgkin Lymphoma: Updated Results of the Open-Label, International, Randomised Phase 3 HD15 Trial by the German Hodgkin Study Group
por: Engert, Andreas, et al.
Publicado: (2017)

Sexual quality of life in Hodgkin Lymphoma: a longitudinal analysis by the German Hodgkin Study Group
por: Behringer, K, et al.
Publicado: (2013)

P037: High breadth whole exome sequencing of circulating tumor DNA identifies novel recurrent genetic alterations in Hodgkin lymphoma
por: Mammadova, Laman, et al.
Publicado: (2022)

P039: HLA expression status and prognostic impact of B-cell content in patients with early-stage unfavorable Hodgkin lymphoma
por: Grund, Johanna, et al.
Publicado: (2022)

Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma
por: Garcia-Marquez, Maria A., et al.
Publicado: (2021)

Assessment of CD52 expression in "double-hit" and "double-expressor" lymphomas: Implications for clinical trial eligibility
por: Craig, Jeffrey W., et al.
Publicado: (2018)

Expanded use of rituximab in the management of non-Hodgkin lymphoma
por: Eichenauer, Dennis A, et al.
Publicado: (2009)

Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis
por: Bröckelmann, Paul J., et al.
Publicado: (2021)

Controversies in the Treatment of Classical Hodgkin Lymphoma
por: Eichenauer, Dennis A., et al.
Publicado: (2018)

Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective
por: Sureda, Anna, et al.
Publicado: (2020)

Impact of the first COVID-19 lockdown in Germany on the rate of acute infections during intensive chemotherapy for Hodgkin lymphoma
por: Jacob, Anne Sophie, et al.
Publicado: (2022)

Evidence of Inbreeding in Hodgkin Lymphoma
por: Thomsen, Hauke, et al.
Publicado: (2016)

P059: Multi-effector cell targeting with half-life extended bispecific scFv in Hodgkin lymphoma
por: Shi, Zhiyuan, et al.
Publicado: (2022)

Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma – Data from the prospective, multicenter phase III HD16 trial
por: van Heek, Lutz, et al.
Publicado: (2022)

P008: Impact of bone marrow involvement on early PET response and progression-free survival in the HD18 trial for patients with advanced-stage Hodgkin lymphoma
por: Voltin, Conrad-Amadeus, et al.
Publicado: (2022)

Therapy-Related Myeloid Neoplasms in Patients Treated for Hodgkin Lymphoma
por: Eichenauer, D.A., et al.
Publicado: (2011)

Radiation Therapy in the German Hodgkin Study Group HD 16 and HD 17 Trials: Quality Assurance and Dosimetric Analysis for Hodgkin Lymphoma in the Modern Era
por: Oertel, Michael, et al.
Publicado: (2022)

Southern Ocean biogenic blooms freezing-in Oligocene colder climates
por: Hochmuth, Katharina, et al.
Publicado: (2022)

S236: HIGH-BREADTH SEQUENCING OF CIRCULATING TUMOR DNA IDENTIFIES NOVEL CLASSIFICATION OF HODGKIN LYMPHOMA
por: Heger, Jan-Michel, et al.
Publicado: (2023)

P024: Predictive Value of Baseline Metabolic Tumor Volume in Early-Stage Favorable Hodgkin Lymphoma – Data from the Prospective, Multicenter Phase III HD16 Trial
por: Van Heek, Lutz, et al.
Publicado: (2022)

T020: Interim PET-guided treatment of early-stage nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the GHSG HD16 and HD17 studies
por: Eichenauer, Dennis A., et al.
Publicado: (2022)

Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced‐stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high‐risk patients from the ECHELON‐1 study
por: Hutchings, Martin, et al.
Publicado: (2021)

P078: Predicting the Health-Related Quality of Life of Hodgkin Lymphoma Survivors: Identification of Risk Factors
por: Stadtbaeumer, Nele, et al.
Publicado: (2022)

P046: Preclinical evaluation of novel repurposed drug combinations in Hodgkin lymphoma
por: Lohmann, Mia, et al.
Publicado: (2022)

Gene expression-based outcome prediction in advanced stage classical Hodgkin lymphoma treated with BEACOPP
por: Jachimowicz, Ron D., et al.
Publicado: (2021)

Involved Site Radiotherapy Extends Time to Premature Menopause in Infra-Diaphragmatic Female Hodgkin Lymphoma Patients – An Analysis of GHSG HD14- and HD17-Patients
por: Rosenbrock, Johannes, et al.
Publicado: (2021)

Hodgkin's Lymphoma and Paraneoplastic Phenomena in the Central Nervous System: A Case Report and Review of the Literature
por: Vetter, Marcus, et al.
Publicado: (2011)

T002: Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group
por: Borchmann, Peter, et al.
Publicado: (2022)

P038: HLA expression patterns of Hodgkin-Reed-Sternberg cells shape a spatially arranged tumor microenvironment in classical Hodgkin lymphoma
por: Müller-Meinhard, Berit, et al.
Publicado: (2022)

S218: CORRELATION BETWEEN PROGRESSION-FREE AND OVERALL SURVIVAL IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA: A COMPREHENSIVE ANALYSIS OF INDIVIDUAL PATIENT DATA FROM RANDOMIZED GHSG TRIALS
por: Bröckelmann, Paul, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ro7faltbdig8aulgfcfagsns8c